Biocept Inc
BIOC
Get informed when a big investor buys or sells
+ FollowMarket Cap$450.79K
Close$
Share Statistics
| Market cap | $450,786.00 |
|---|---|
| Enterprise Value | $4.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-56.78 |
| Beta | 0.6 |
| Outstanding Shares | 1,036 |
Return
| Return on Equity | -12035.17% |
|---|---|
| Return on Assets | -157.91% |
| Return on Invested Capital | -216.85% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.02 |
| Price to Sales | -0.0 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -1.42 |
| Enterprise Value to EBIT | -0.13 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.27 |
| Debt to Equity | 38.16 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biocept, Inc.
50 employees
CEO: Soon Kap Hahn Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or C...